Diagnostic Approach to Glycogen Storage Disease

Initial Evaluation

The presence of hepatomegaly with or without hypoglycemia is the hallmark presentation requiring immediate workup, as recommended by the Genetics in Medicine society 1, 2
The timing and severity of hypoglycemia helps differentiate GSD types, with severe hypoglycemia 3-4 hours after feeding suggesting GSD I, while less severe hypoglycemia suggests GSD III, according to the Genetics in Medicine guidelines 3
Muscle involvement, such as proximal and distal weakness, elevated CK, exercise intolerance, or cardiomyopathy, suggests GSD III or other muscle GSDs, as noted by the Genetics in Medicine society 4, 2

Blood glucose, lactate, uric acid, and hepatic profile with liver function studies, including AST and ALT, are essential first-line tests, as recommended by the Genetics in Medicine society 1, 4, 5
Plasma CK, total and free carnitine, acylcarnitine profile, amino acids, urinalysis, and urine organic acids are also crucial tests, according to the Genetics in Medicine guidelines 1, 4, 5, 2, 6
The American College of Medical Genetics and Genomics recommends genetic testing, including gene panels for G6PC, SLC37A4, and AGL genes, for suspected hepatic GSDs 7

For patients presenting with hepatomegaly, hypoglycemia, and elevated transaminases, the diagnostic algorithm involves drawing critical blood samples, checking lactate and uric acid, assessing ketone status, and ordering genetic testing, as outlined by the Genetics in Medicine society 1, 7
For patients with muscle weakness, elevated CK, and hepatomegaly, the algorithm involves measuring CK, AST, ALT, and assessing for hypoglycemia, performing EMG/nerve conduction studies, and ordering genetic testing, according to the Genetics in Medicine guidelines 4, 2, 7

Liver and/or muscle biopsy with proper tissue processing is required for enzymatic analysis and histology, as recommended by the Genetics in Medicine society 1, 4, 5, 6
Histopathologic findings in GSD III liver biopsy include vacuolar accumulation of non-membrane-bound glycogen, increased glycogen content, structurally abnormal glycogen, and fibrosis, as noted by the Genetics in Medicine society 5

Regular ultrasound surveillance every 6-12 months is necessary to monitor for hepatic adenomas, and alpha-fetoprotein and ultrasound screening are recommended for hepatocellular carcinoma risk, as outlined by the Praxis Medical Insights society 7
Regular echocardiograms and CK monitoring are essential for GSD IIIa to detect cardiomyopathy and progressive myopathy, according to the Praxis Medical Insights guidelines 7

The American College of Medical Genetics and Genomics recommends that plasma carnitine levels, along with acylcarnitine profiles, are essential diagnostic tests to differentiate glycogen storage diseases from fatty acid oxidation disorders, though they are not specific for diagnosing GSD itself 8, 9
The main utility of plasma carnitine is to exclude fatty acid oxidation disorders from the differential diagnosis, which can present similarly with hypoglycemia and hepatomegaly but have fundamentally different pathophysiology and treatment 8, 9
In GSD, normal or mildly decreased free carnitine with normal acylcarnitine profiles is expected, whereas fatty acid oxidation disorders show markedly abnormal acylcarnitine patterns with specific elevations depending on the enzyme defect 8, 9
The acylcarnitine profile helps distinguish hypoketotic hypoglycemia of GSD I from the hypoketotic hypoglycemia of fatty acid oxidation disorders, both presenting without ketones during fasting, but the acylcarnitine patterns differ dramatically 9, 10

Total and free carnitine levels are part of the standard metabolic workup when evaluating hepatomegaly with hypoglycemia, as recommended in the primary evaluation panel 8, 9
Normal carnitine levels with normal acylcarnitine ratios support GSD over primary carnitine deficiency or fatty acid oxidation disorders, which would show low free carnitine and abnormal acylcarnitine patterns 8, 9
GSD patients typically maintain adequate ketone production during hypoglycemia, especially GSD III, VI, IX, which contrasts with the hypoketotic hypoglycemia seen in fatty acid oxidation disorders where carnitine and acylcarnitine abnormalities are prominent 10, 11

Elevated lactate + elevated uric acid + normal carnitine = strongly suggests GSD I rather than fatty acid oxidation disorder, as recommended by the American College of Medical Genetics and Genomics 10, 11, 12
Normal lactate + normal uric acid + hyperketosis + normal carnitine = suggests GSD III, VI, or IX rather than fatty acid oxidation disorder 10, 11

Do not rely on plasma carnitine alone to diagnose or exclude GSD, as the diagnosis requires genetic confirmation or enzymatic analysis, according to the American College of Medical Genetics and Genomics 8, 9
Always order the complete acylcarnitine profile, not just total and free carnitine, as the pattern of individual acylcarnitines provides the most diagnostic information for differentiating metabolic disorders 8, 9